BioSpace News Archive

Furthering its commitment to deliver the benefits of simple, high viability cell sorting solutions globally, NanoCellect Biomedical announced it has completed agreements with several key partners to distribute its WOLF

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that two seladelpar presentations will be delivered during the Digital International Liver Congress™ 2020 of the European Association for the Study of Liver (EASL) which will be held online August 27 th – 29 th . The presentation titled “D

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that data from its VIR-2218 clinical program will be featured at the European Association for the Study of the Liver (EASL) Digital International Liver Congress™ from August 27-29, 2020. VIR-2218 is an investigational small interfering ribonucleic acid (siRNA) that mediates RNA interference (R

Galderma is partnering with rosacea sufferer and celebrity stylist, Brad Goreski, for the national awareness campaign, Face Up to Rosacea, to encourage people frustrated with this chronic skin condition to take action by consulting with a dermatologist.

Columbus Children’s Foundation (CCF), a national leading non-profit biotech organization helping children with ultra-rare genetic diseases, announced today that Krystof Bankiewicz, M.D., Ph.D., has been named president and chief executive officer.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announ

IONpath, Inc., the leader in high-definition spatial proteomics, today announced the appointment of Sander Gubbens, PhD, as its new CEO.

TerrAscend Corp. (“TerrAscend” or the “Company”) (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today reported financial results for its second quarter ending June 30, 2020.

Can-Fite BioPharma Ltd. announced it will conduct a conference call with investors to review financial results of its second quarter and provide an update on clinical and corporate developments, including its advanced stage drug candidates Piclidenoson and Namodenoson.

Enanta Pharmaceuticals, Inc. announced that clinical data from Enanta’s wholly-owned development programs for non-alcoholic steatohepatitis and hepatitis B virus have been accepted for presentations at the European Association for the Study of the Liver Digital International Liver Congress 2020 being held August 27-29, 2020.